Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2009 | 2 |
2011 | 2 |
2012 | 1 |
2013 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Blood. 2013 Jan 17;121(3):489-98. doi: 10.1182/blood-2012-05-431379. Epub 2012 Dec 5.
Blood. 2013.
PMID: 23223358
Free PMC article.
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T.
O'Hare T, et al. Among authors: adrian lt.
Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.
Cancer Cell. 2009.
PMID: 19878872
Free PMC article.
Item in Clipboard
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ.
O'Hare T, et al. Among authors: adrian lt.
Blood. 2011 Nov 10;118(19):5250-4. doi: 10.1182/blood-2011-05-349191. Epub 2011 Sep 8.
Blood. 2011.
PMID: 21908430
Free PMC article.
Item in Clipboard
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, Tyner JW, Deininger MW, Druker BJ.
O'Hare T, et al. Among authors: adrian lt.
Cancer Res. 2013 Jun 1;73(11):3356-70. doi: 10.1158/0008-5472.CAN-12-3904. Epub 2013 Apr 10.
Cancer Res. 2013.
PMID: 23576564
Free PMC article.
Item in Clipboard
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW.
Snead JL, et al. Among authors: adrian lt.
Blood. 2009 Oct 15;114(16):3459-63. doi: 10.1182/blood-2007-10-113969. Epub 2009 Aug 25.
Blood. 2009.
PMID: 19706883
Free PMC article.
Item in Clipboard
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ.
Eide CA, et al. Among authors: adrian lt.
Cancer Res. 2011 May 1;71(9):3189-95. doi: 10.1158/0008-5472.CAN-10-3224. Epub 2011 Apr 19.
Cancer Res. 2011.
PMID: 21505103
Free PMC article.
Item in Clipboard
Cite
Cite